Arca
Skip to content

IL17A: Interleukin-17A

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity.

  • Drugs that act on it: 11
  • With a US drug page: 3
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
BimekizumabApprovedInterleukin 17A inhibitorInhibitor—
IxekizumabApprovedInterleukin 17A inhibitorInhibitor—
SecukinumabApprovedInterleukin 17A inhibitorInhibitor—
Afasevikumab—Interleukin 17A inhibitorInhibitor—
CJM-112—Interleukin 17A binding agentBinding agent—
Izokibep—Interleukin 17A inhibitorInhibitor—
M-1095—Interleukin 17A inhibitorInhibitor—
Perakizumab—Interleukin 17A inhibitorInhibitor—
Remtolumab—Interleukin 17A inhibitorInhibitor—
Tibulizumab—Interleukin 17A inhibitorInhibitor—
Vunakizumab—Interleukin 17A inhibitorInhibitor—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Psoriasis vulgaris
0.60
Immune system disorder
0.51
Spondyloarthropathy
0.50
Arthritic joint disease
0.40
Pustular psoriasis
0.37

Drugs and mechanisms are from ChEMBL CHEMBL3390822 (CC BY-SA 3.0). Gene name, function (UniProt Q16552, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.